Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes

As a prognostic biomarker for progression of diabetic nephropathy, albuminuria fails in terms of sensitivity and specificity. Better urinary or plasma biomarkers are needed that can predict which diabetic patients are at highest risk for progression. Bhensdadia et al. report proteomic investigations that identified urinary haptoglobin as a potential prognostic biomarker for progressive diabetic nephropathy. Although as a single marker urinary haptoglobin adds little to albuminuria, together the two appear to provide better diagnostic accuracy than albuminuria alone. Excess adiposity is the most important risk factor for the development of insulin resistance and type 2 diabetes (1). However, mechanisms whereby body fat induces insulin resistance in distant tissues are not well understood. Recent evidence indicates that obesity may be an inflammatory markers.
  • Prognostic biomarkers
  • Diabetic nephropathy biomarkers
  • Diabetes: Clinical trials and new biomarkers under development
  • Pharmacotherapy in treatment of diabetes
  • Molecular markers for both metabolic syndrome and hypoglycemia responses
  • Inflammatory markers: Type 2 diabetes
  • New drug treatments and devices for diabetes: current research

Related Conference of Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes

Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes Conference Speakers